Rocket Doctor AI Inc. Announces Non‑Brokered Private Placement of Unsecured Convertible Debentures

Rocket Doctor AI Inc., a U.S. technology firm listed on the OTC Bulletin Board, disclosed on 17 November 2026 that it has initiated a non‑brokered private placement of unsecured convertible debentures. The move marks a strategic effort to secure flexible financing while preserving equity structure and signals a readiness to pursue forthcoming growth initiatives in the artificial‑intelligence‑driven diagnostics sector.

Key Transaction Details

  • Issuer: Rocket Doctor AI Inc.
  • Security: Unsecured convertible debentures
  • Placement Type: Non‑brokered private placement
  • Target Investors: Accredited and institutional investors with an interest in high‑yield, convertible debt offerings
  • Purpose: To generate capital that can be deployed toward product development, regulatory approvals, and strategic acquisitions within the AI‑powered medical diagnostics domain

While the announcement does not disclose the specific terms—such as coupon rate, maturity date, or conversion premium—the structure of an unsecured convertible debenture typically offers investors a fixed income component coupled with an equity conversion option, enabling upside participation in the company’s valuation trajectory.

Market Context

Rocket Doctor AI Inc.’s stock has demonstrated volatility in the current year, trading at $0.3165 on 12 November 2026 after reaching a 52‑week high of $0.6625 on 30 November 2025 and a low of $0.3001 on 10 November 2026. With a market capitalization of approximately $32 million USD, the firm occupies a niche position within the broader AI health‑tech ecosystem.

The decision to raise debt through a private placement reflects a calculated balance between leveraging debt to finance expansion and maintaining control over dilution. By offering convertible features, Rocket Doctor AI Inc. positions itself to attract investors who value both income and the potential upside of equity conversion, thereby aligning the interests of new capital contributors with long‑term shareholder value.

Forward‑Looking Perspective

The company’s leadership has emphasized that the proceeds will be earmarked for accelerating the development of its next-generation AI diagnostic platform, which promises to enhance diagnostic accuracy while reducing operational costs for healthcare providers. In addition, the firm intends to use a portion of the raised capital to pursue strategic partnerships and potential acquisitions that complement its core technology stack.

Given the company’s current valuation metrics—most notably a negative price‑earnings ratio of –2.56—the issuance of convertible debt presents an attractive avenue to secure capital at a comparatively lower cost of capital than traditional equity rounds. Moreover, the private placement’s non‑brokered nature underscores Rocket Doctor AI Inc.’s confidence in its investor base and its ability to execute on an efficient capital‑raising process.

Conclusion

Rocket Doctor AI Inc.’s initiation of a non‑brokered private placement of unsecured convertible debentures signals a proactive stance toward securing the financial resources necessary to advance its AI‑enabled diagnostics solutions. By leveraging the convertible structure, the company is poised to attract investors who appreciate both the safety net of fixed income and the upside potential of equity conversion, thereby positioning itself for sustained growth in a highly competitive market.